Effects of Chemotherapy on the Development of Lymphedema in Breast Cancer Patients: A Retrospective Analysis
-
By
-
Liqin Wang
-
Yuemin Weng
-
Weiqi Wei
-
Jun Bu
-
Cici Zhang
-
April 27, 2026
-
Clinical Scorecard: Effects of Chemotherapy on the Development of Lymphedema in Breast Cancer Patients: A Retrospective Analysis
At a Glance
| Category | Detail |
|---|
| Condition | Breast Cancer-Related Lymphedema (BCRL) |
| Key Mechanisms | Chemotherapy regimens, treatment duration, and timing of chemotherapy |
| Target Population | Patients with pathologically confirmed breast cancer undergoing surgical treatment |
| Care Setting | Single-center, retrospective cohort study |
Key Highlights
- BCRL occurred in 15.4% of patients studied.
- Taxane-based regimens significantly associated with increased BCRL risk (OR = 4.018).
- Long-course chemotherapy linked to higher BCRL incidence (OR = 4.887).
- Combination of neoadjuvant and adjuvant chemotherapy associated with BCRL (OR = 4.50).
- Vigilant monitoring for BCRL recommended for patients receiving specific chemotherapy regimens.
Guideline-Based Recommendations
Diagnosis
- Monitor for symptoms of BCRL in breast cancer patients post-surgery.
Management
- Consider risk factors such as chemotherapy regimen and surgical history in BCRL management.
Monitoring & Follow-up
- Implement regular assessments for BCRL in patients receiving taxane-based or long-course chemotherapy.
Risks
- Increased risk of BCRL associated with extensive axillary surgery and specific chemotherapy regimens.
Patient & Prescribing Data
201 patients with primary breast cancer who underwent surgery.
Chemotherapy regimens should be tailored considering the risk of BCRL.
Clinical Best Practices
- Utilize a multidisciplinary approach for treatment planning in breast cancer patients.
- Educate patients on the signs and symptoms of BCRL for early detection.
- Incorporate risk stratification in treatment protocols to mitigate BCRL risk.
References
